Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc. (ANEB): 2 pipeline candidates · ~21 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
20.8 months
D/E 0.19 · 0% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for Anebulo Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$18.8M
Cash
$9.0M
Quarterly Burn
$1.3M
Runway
20.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| selonabant | Phase 1 |
| selonabant (formerly ANEB-001) | Phase 2 |
Frequently asked questions
How many drug candidates are in Anebulo Pharmaceuticals, Inc.'s pipeline?
Anebulo Pharmaceuticals, Inc. (ANEB) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Anebulo Pharmaceuticals, Inc.'s lead drug candidate?
Anebulo Pharmaceuticals, Inc.'s most advanced tracked candidate is selonabant (Phase 1) for Healthy Volunteers.
What is Anebulo Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Anebulo Pharmaceuticals, Inc. has approximately 20.8 months of cash runway.
What is Anebulo Pharmaceuticals, Inc.'s market capitalization?
Anebulo Pharmaceuticals, Inc.'s market capitalization is approximately $18.8M.
Who is the CEO of Anebulo Pharmaceuticals, Inc.?
Mr. Richard Anthony Cunningham is the chief executive officer of Anebulo Pharmaceuticals, Inc. (ANEB).
Get the full picture on Anebulo Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.